INVESTORS

PRESS RELEASES
2011

06.29.11 - GENSPERA ENTERS AGREEMENT WITH UNIVERSITY OF COPENHAGEN FOR                    PRODUCTION OF THAPSIGARGIN

05.02.11 - GENSPERA COMPLETES $2.2 MILLION PRIVATE PLACEMENT

03.28.11 - GENSPERA ANNOUNCES FIRST PATIENT DOSED AT CANCER THERAPY
                   & RESEARCH CENTER IN ONGOING G-202 PHASE I TRIAL

03.17.11 - GENSPERA RECEIVES PATENT ON SECOND PROSTATE-TARGETING
                   ONCOLOGY DRUG

2010

11.30.10 - GENSPERA EXPANDS G-202 PHASE I CLINICAL PROGRAM

11.04.10 - GENSPERA AWARDED TWO FEDERAL GRANTS

08.17.10 - GENSPERA APPOINTS DR. BO JESPER HANSEN TO ITS BOARD OF DIRECTORS

08.10.10 - GENSPERA RECEIVES ADDITIONAL PATENT ON LEAD ONCOLOGY PRODRUG, G-202

08.03.10 - GENSPERA ACQUIRES RIGHTS TO CANCER IMAGING TECHNOLOGY

05.18.10 - SOURCE CAPITAL GROUP SPRING SMALL CAP VIRTUAL CONFERENCE

02.02.10 - GENSPERA RECEIVES PATENT ON SECOND ANTI-CANCER DRUG, G-115

01.27.10 - GENSPERA ANNOUNCES FIRST CANCER PATIENT TREATED WITH G-202
                    IN PHASE I TRIAL

2009

12.15.09 - GENSPERA RECEIVES APPROVAL TO COMMENCE G-202 PHASE I TRIAL
                    AT THE UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER

11.03.09 - GENSPERA'S COMMON STOCK COMMENCES TRADING

09.11.09 - GENSPERA RECEIVES FDA APPROVAL FOR G-202 PHASE I CANCER TRIAL